It functions as a growth hormone for tissue of the reproductive organs, and it enhances growth of the myometrium to prepare it for the implantation of a possible embryo. During the menstrual cycle, estradiol produced by the growing follicles increase and triggers, via a positive feedback system, the hypothalamic-pituitary events that lead to the luteinizing hormone surge, inducing ovulation. In the luteal phase, it works in conjunction with progesterone, prepares the endometrium for implantation. During pregnancy, estradiol increases due to placental production. It is usually tested at day 3 in the follicular phase of the menstrual cycle.
Estradiol (E2)
Estradiol (E2)
Estradiol (E2, or also spelled oestradiol) is an oestrogen steroid and is the major female sex hormone.
Estradiol is the most biologically active oestrogen and is the most abundant form of oestrogen in premenopausal women. Levels of estradiol in premenopausal women are highly variable throughout the menstrual cycle. Estradiol levels are of value in the induction of ovulation, assessment of amenorrhoea, evaluation of testicular dysfunction or gonadal dysgenesis. They are also regularly used as part of fertility investigations and to determine suitable doses of hormones during individualised treatment protocols pre IVF.
A sustained reduction in estradiol levels results in reduced calcium resorption, accelerated loss of bone density and a subsequent increase in triglyceride levels. In patients with overt POI, they are at a higher risk for earlier onset cardiovascular disease and osteoporosis. Low levels indicate ovarian insufficiency, menopause, POI, PCOS, hypopituitarism, hypogonadism, severe eating disorders and genetic causes such as Turner syndrome.
Clinically significant increased levels can occur in with patients with ovarian or adrenal rumours, gynaecomastia, testicular tumours and adrenal hyperplasia and in children with precocious puberty in children; and warrant further investigation.
Case Study
Delivering True Innovation
Our Services
5mL venous serum
Enfer Medical
Tests/Assays
Enfer Medical offers chemiluminescent microparticle immunoassay (CMIA) technology for the quantitative assay for Estradiol ( E2). This test is CE-IVD certified.
Patient
Request Form
For clients using the Enfer Medical Client Portal, the Enfer Medical Patient Request Form (PRF) will be generated when you have completed your “Test Request” within the portal linked below.
Please note that samples suspected of containing high risk pathogens such as Mycobacterium tuberculosis should be clearly identified on the form and packed separately from other samples.
Results are available next working day.
This assay is available seven days a week.
Packaging
The packaging/preparation of samples for delivery to the laboratory are required to be in adherence to all national regulations for the safe transport of biological materials. HSE guidance can be reviewed HERE.
There are specific packaging instructions and labelling requirements requiring triple packaging including:
- Primary leak-proof container – tube or vial containing the sample.
- Secondary watertight container, with absorbent material, intended to protect the primary container.
- Outer container protects the secondary container.
- Patient Request forms must be placed between the secondary container and the outer shipping container.
Further information on the packaging/preparation of samples for delivery to the laboratory is contained within the Enfer Medical Laboratory User Manual which clients are provided with.
Storage & Stability
Specimens must be tested within 7 days of collection and stored at 2-8°C.
Samples
In addition to the packaging of samples, the transport/delivery of clinical samples to the laboratory is required to be in adherence to all national regulations for the safe transport of biological materials. Enfer Medical provides a fully compliant logistics service, aligned with clients’ testing requirements.
Prompt transport of specimens:
To ensure prompt testing of samples and release of results within the published test turnaround times, samples should arrive to the laboratory by 18:00. Test turnaround time is measured from receipt of the sample at the laboratory until the time the authorised results are reported to users.
of Samples
In rare cases specimens may not be suitable for testing on arrival to the laboratory. In that case the sample will be rejected at the receipt stage and the service user will be notified immediately and an explanation as to why the sample could not be processed will be provided. Reasons why samples cannot be processed include but are not limited to:
- Samples received beyond the stability limits and/or not at the correct temperature indicated for each test.
- Incorrect sample type received.
- Leaking samples, sample not received or sample insufficient for analysis as stated below within sample requirements.
- Non-compliant samples or request forms i.e. those missing sample date information, missing sample test request and/or missing sample site/type information.
- Samples received without the necessary patient identifiers.
Our Services
Quantitative results for Estradiol (E2) are reported in numeric value in pmol/L. Please contact us for more information on the reference ranges used at Enfer Medical.
Accessing
Your Results
Following receipt at the Laboratory, results should be available on the next working day and will be reported to the referring clinician via the Enfer Medical Client Portal or in a format agreed with clients.
Established clients can login to the portal using the link above.